CATEGORIES ENDOVASCULAR: Hypertension Therapies and Renal Denervation

KEYWORDS Renal Denervation

TCT-769

Renal denervation: more ablative points major reduction in blood pressure?

Cinzia Moncalvo,¹ Vincenzo Puma,¹ Giuseppe Celano,¹ Angelo Laurenza,¹ Giuseppe Carosio,¹ Paolo Cioffi¹ ¹Clinica Città di Alessandria, Alessandria, Italy

BACKGROUND Data published in the study Simplicity III reported that the effectiveness of the procedure is directly related to the number of ablative points with a threshold calculated as about 14 points. In our experience this threshold has been exceeded since we use the device Enlightn St Jude whose conformation allows both a more favorable contact of the electrodes with the vessel wall and the possibility of varying those points more precisely. This result can be achieved only beginning the ablation as distally as possible in the renal arteries, performing the procedure even in the branches when they have a minimum diameter of 4 mm. The purpose of our study was to see if a larger number of points of ablation were related to a greater effectiveness of the procedure.

METHODS In our center 29 patients (17 men. Average age 58.4 \pm 14 years) with resistant hypertension were submitted to transcatheter renal denervation between November 2011 and May 2015. 12 patients had signs of hypertensive vascular damage. All of them were taking an average of 4 antihypertensive drugs in dosage ceiling, including a diuretic. The values of mean arterial pressure were: 176/98 \pm 17/ 14 mmHg. For all patients we used the femoral arterial access. All patients were treated with dual anti platelet therapy for 3/6 months after the procedure. 7 patients had complex renal anatomy: 2 patients had superior polar arteries, 1 patients presented one superior and one inferior polar artery and 4 patients presented an early bifurcation (length of the proximal segment <10 mm), all arteries had a diameter >4 mm. 16 patients, treated from March 2014 to May 2015, were treated with an average of 24-36 ablative points overall compared with the first group of patients in which the ablative points were only 16.

RESULTS All patients were treated successfully. Renal function remained stable. The average pressure was reduced by about 15 mmHg at six months in the group of patients treated with 16 ablative points, whereas in patients treated with 24-36 ablative points this reduction was approximately 27 mmHg. One patient of the first group was hospitalized for hypertensive crisis seven months after the procedure, the values of blood pressure normalized after about one year and are still stable. All patients have gradually reduced the number of antihypertensive drugs (1-2 against 4 or more pre-procedure). Computed tomography angiography of the patients in which the ablation was performed very distally and showed a more important parietal notch of the renal artery after the procedure (16) documented the absence of parietal complications three months after the procedure.

CONCLUSIONS Our experience confirms that renal denervation is an effective procedure in the treatment of hypertensive patients refractory to medical therapy. A larger number of ablative points seems to be strongly related to an increased efficacy of treatment.

CATEGORIES ENDOVASCULAR: Hypertension Therapies and Renal Denervation

KEYWORDS Ambulatory blood pressure monitoring (ABPM), Renal sympathetic denervation, Resistant hypertension

TCT-770

Catheter-based renal sympathetic denervation for resistant hypertension: A meta-analysis of randomized trials

Mohammad M. Ansari,¹ Daniel C. Garcia,² Rhanderson N. Cardoso,³ Eduardo de Marchena⁴

¹University of Miami- Jackson Memorial Hospital, New York, NY; ²Ochsner Clinic Foundation, New Orleans, LA; ³University of Miami/ Jackson Memorial Hospital, Miami, FL; ⁴University of Miami Miller School of Medicine, Miami, FL

BACKGROUND Percutaneous renal artery denervation has been shown to decrease blood pressure among patients with resistant arterial hypertension. We present in this review a meta-analysis of all randomized controlled trials evaluating effectiveness and complications of catheter-based RDN for blood pressure control in patients with resistant hypertension.

METHODS We searched Pub Med, Cochrane and Scopus were systematically searched up for all RTCs up to June 2015. Primary outcomes were 6 months reduction of office systolic and diastolic blood pressure. Secondary outcomes were 24 hours systolic blood pressure reduction and more than 10 mmHg systolic blood pressure reduction. We used fixed or random Effect analysis using the Cochrane Handbook of Systematic Reviews.

RESULTS Out of 860 articles, five RCTs were included. The pooled data provided a total of 776 patients, being 476 in the RDN group and 300 patients in the control group with mean 6 months of follow-up. Both groups had office systolic and diastolic blood pressures significantly decreased (p<0.05). There was no significant difference in SBP reduction between the two groups but RDN had higher DBP reduction (p<0.05). RDN group presented with a trend towards higher decrease of 24-hours systolic blood pressure (mean reduction -5.22; p=0.07). RDN trended to present more patients who had \geq 10 mmHg SBP decrease (p=0.1) (Figure 1).

Office SB	r								
	Renal	benerve	tion		ice deal			Mean Difference	thean Ofference
Study or Subgroup	Litean	50	Total	the an	50	2064	Vergh	N, Random, 97% C	N, Random, 975-CI
Elemate 2015		15		- 26	- 22		10.5%	20:00 (7:34, 32:00	
POKUSTAROK 2012	-22	23	12			14	10.01	-32.00 (+48.85, -16.25	
N954 2015	124	- 55		14.3		- 25	21.04	1 90 10 01, 2 81	
Symplexy 2	- 4 4 5						21.7%	-2200 (28.20, -18.00	
Northernal N		****						-414(114), 444	1
Turkad (99%-CD)			478			308	105.05	4.88 [28.98, 6.87	-
Helenopeneily Tau ^a +	223.87,0	Chiff = 10	17 82.4	- 400 -	0.0000	HLP.	32%		has to be an
Teather overall effect.	Z=0.90	9=23	b					6.	-100 -90 0 50 100
000 DE			-						
Office DE	SP.			-				and the second sec	Barro California
Charles on Endorson	menal lines	CHEMITY I	Total I	0		Testeri	No.	Al Deplemental	Al Restore Alls Ci
And the period set	the set	- 20	1008	-	- 22	1000	All line	THE PARTY AND A COLORED	IV, Ramoom, KON CJ
Pokushalok 2012	-10		12	-3		14	22.2%	-7.00 (11.50, -2.47)	
Pusa 2015	12,4	3.5	9.2	1.1			28.0%	4.1011.34,1.14	
Sympochy 2	-12						21.2%	-1200010.12,-7.001	
Discriminal 1	-8.6	11.9	161	-4.5	12.8	1.71	26.9%	-2100 (-4136/ 0.101	1
Turkel (\$5% City			467			290	100.0%	491[856.431]	
ALL CONTRACTOR OF A					00001	Pel	17%		
removements like a	18.25, 0	AF = 35	37. # *	28.48					100 00 00 000
Test for overall effect.	19.25, C Z+2.09	74° = 75 (7 = 0.5	37,#* 0	24.1				(ac	100 -50 8 50 100
Test to overall effect.	19.25,0 Z+2.09	//* = 35 (? = 0.5	57,#* 0	24.1				Fac	180 -68 8 60 108 rs Renal Denenation Favors Control
24 hours	2+289 5 SB	е-э е-э Р	57,#* 0	59.41				Fast	180 -68 8 60 109 rs Renal Denenation Favors Control
24 hours	2+228 SB	P=35 P=0.5 P	57, #* 0	0	introl			Fairs Mean Difference	teo da 8 do 100 n Renal Demensión Favors Control Mean Difference
24 hours	SB Renat Bean	07 = 35 (7 = 0.5 P benerva 50	57, #** 4) dion 3064	Gillean	icetha G2	Total	Weight	Fairs Mean Difference IV, Random, 895-CI	180 - da é fé sol ra Renal Denenation Favora Control Mean Difference M. Raedow, 994-CI
24 hours	2+239 SB Renal Bean -32	P = 25 P = 0.5 P benerva 50 23	57, #* 6) fion 13	Ci Bran	withol 50 21	Total 14	Weight	Fait Mean Difference IV, Random, 995-CI -33.01 (-48.05, -56.20)	100 -fit & 60 100 rs Renal Denenation Favors Control Mean Otherance M, Random, 199-CI
2.4 hours Study of Subgroup Potential 2012 Potential 2012 Potential 2012	18.25.3 2 + 2.29 SB Renal Brean -32 -4.1	P 0 0 0 0 0 0 0 0 0 0 0 0 0	57, #** 0 13 52	Elean 1-45	1000 100 21 2.2	Telal 14 54	Weight 0.5% 35.9%	Fair Mean Difference N. Random, 995-CI -33.00 (+84.65, -16.59) 0.58 (+1.01, 201)	100 - 42 8 50 100 rs Renal Demonstran Favors Control Mean Difference M, Random, 65%-Ci
Testbrowski fair 2.4 hours Staty of Salaping Polychalor 2012 Ross 2015 Renality 2	18.25, 3 2 + 2.29 SB Renal Bean -32 -4.1 -11	P 20 4.5 15	57, ef = 6 13 52 49	0 Beast 1 -65 -3	100 100 21 22 19	Total 14 54 51	Weight 0.5% 25.2% 23.3%	Fait Mean Difference N. Random, 895-CI -33.00 (+48.65, rid-39) 0.581(+1.07, 201) -8.00()14.73, r1.30]	100 - 62 8 50 100 rs Renal Demonstran Favora Control Mutan Difference M. Renalam, 95% D
Testtroveni effect 24 hours Stats of Talapoop Policihalio 2012 Rosa 2015 Borgán fr.2 Borgán fr.2 Borgán fr.2	18.25, 3 2 + 2.29 SB Renal Bean -32 -4.1 -4.75	0/*= 35 (? = 0.5 P benerve 10 27 4.5 15 15 15	57, d** 0 fion 13 52 49 353	0 Beat 1 -46 -3 -479	100 100 21 22 19 17 25	Total 14 54 51 171	0.5% 35.9% 23.9% 32.5%	Fait Mean Difference N, Randon, 995-CI (35.00 §-48.05, rd.592 0.58 §-1.01, 201 (8.00) f-4.72, rl.302 (-1.96 §-4.93, 1.07)	100 - da 6 50 100 In Runal Demonstran Favora Control Misan Difference IV, Random, MM-CI
Test troveni effect 2.4 hours Test troveni effect 2.4 hours Test troveni effect Test tro	18.25, 0 2 × 2.09 SB Renal Mean -02 -0.1 -0.1 -0.1 -0.2 -0.2	67 = 35 (7 = 0.5 P benerve 50 20 4.5 15 15.11	57, d* 0 1044 13 52 43 153	6 Bean -45 -3 -479	1000 100 21 32 13 17 25	Todal 14 54 51 171	Weight 8.5% 25.3% 32.5%	Fant Mean Difference N, Randon, 89% CJ (20.00144, 20.01 (20.0114, 20.01 (20.0114, 20.01 (20.0114, 20.01) (20.0114, 20.01) (20	100 - da 8 60 100 In Runal Evenantion - Ruoss Control Masso Bifference M, Reeden, MP, Co
Test troveni effect 2.4 hours Study or Subgroup Pokushalor 2012 Rompicity 2 Sprojecty 2 Total (956-CB	18.25, c 2+ 2.19 SB Runal Baan -32 -4.1 -71 -4.25	67 = 35 (7 = 0.5 P benerve 50 20 4.5 15 15 15	57, d* 0 1044 13 15 15 15 160 10 10 10 10 10 10 10 10 10 10 10 10 10	1 46 -3 -479	10 10 21 22 19 17 25	Total 14 54 51 171 290	Weight 85% 353% 323% 325%	Fam Mean Difference N, Random, 195-CI 43.00148.06.40.50 48.00144.70, 1.301 -1.9614.30, 1.071 -5.271.43.04, 0.401	180 - 161 8 60 109 Is Renal Demendion Favors Control Mean Difference Mean Difference Mean Difference
Tests overal effect 2.4 hours Prescheite 2012 Ross 2015 Benglicky 2 Benglicky 2 Total (85%-C) Helerogeneity Tax ⁴ effect	18.25, c 2+2.09 SB Rumal Mean -32 -4.1 -01 -4.75 21.09, C	20 P = 0.5 P benerve 50 20 4.5 15.11 15.11 15.21 15.21	57, d*+ 6 <u>Total</u> 13 52 83 353 467 62, d*+	6 Bean -16 -3 -479 2/P+2	100 10 21 22 13 17 25 10071,1	1944 14 54 51 171 290 7+ 30	Weight 85% 353% 323% 125%	Fant Mean Difference N, Randon, 1915 CJ 0501 (+137, 2016) 48.00 (+4.77, 4.130) 49.00 (+4.77, 4.130) 41.00 (+4.30, 1.07) -5.22 (-50.84, 0.40)	100 - 50 0 50 100
Test troveni effect 24 hours Staty or Teleprop Posshaler 2812 Bonglich? Bonglich? Test (56-C) Test (56-C) Test (56-C)	18.24; c 2+2.29 SB Renall -32 -4.1 -11 -4.75 21.00; C Z=1.82	20 P = 0.5 P benerve 15 15 15 15 15 15 15 15 15 15	57, 47- 60 <u>Total</u> 13 52 457 457 457 52, 47 =	1 -16 -3 -479 2(9+2	100 10 21 32 19 17.25 100r1	1944 54 51 171 290 7+ 10	0.5% 25.2% 22.5% 100.0%	Fam Mean Difference N, Random, 975-CJ -53-301-48-66,-66-30 -559-147, 201 -8.003-54,78, -1.30 -1.36-[4-30, 1.07] -5.22-[-50.44, 8.40] Fan	Hea Billion Fault Control
Testforowal effect 24 hours Testforowal effect 24 hours Testforowal 2012 Ross 2015 Ross 2015	18.24; c 2+2.29 SB Remail Beam -32 -4.1 -4.1 -4.1 -4.75 22.99; C 2=1.82/ nHg	M*= 25 (? + 0.5 Deserve 10 22 4.5 15 15 15 11 15.11 M*+ 22 F = 0.8	13 13 13 13 13 13 15 15 15 15 15 15 15 15 15 15 15 15 15	1 -46 -3 -429 2/P+2 educ	100 11 12 13 17 15 17 25 10 17 25	Total 54 51 171 290 *= 10	Weight 8.5% 25.5% 12.5% 100.0%	Fact Mean Difference <i>IV</i> , Randow, 1995, CJ (2005) 41, 69, 69, 59 (2005) 41, 69, 69, 59 (2005) 41, 79, 138 (2005) 41, 71, 138 (2005) 41, 71, 138 (2005) 41, 107 (2005) 41,	180 - 49 50 100 Near Determined on Fault Control Near Determined on the Control Near Determ
Test over determined for the test over determined to the t	10.24, c 2+239 SB Ramati Baan -32 -4.1 -4.15 -22.09, c 2-1.62 - nHg Ramati	27 45 15 15 15 15 15 15 15 15 15 1	60 10 13 52 457 457 457 457 457 457 457 457	1 -4.5 -4.79 2/P+2 cduo	100 10 12 13 17 25 17 25 17 25 100 10 10 10 10 10 10 10 10 10 10 10 10	Total 54 51 121 296 ** 80	Weight 8.5% 25.3% 32.5% NBL0%	Fact Mean Difference N. Readers, 1954 (2) (2) 01 (44:06) (4) (4) 01 (44:06) (4) (4) (4) (4:05) (4) (4:44:167) (5) (4:44:167) (5) (4:44:167) (5) (4:44:167) (5) (4:44:167) (6) (4:44:167) (6) (4:44:167) (7) (7) (7) (7) (7) (7) (7) (7) (7) (7)	180 - da 8 60 100 Is Ranal Demension - Favors Control Maan Difference Maan Difference M
Test or over a field of the second se	10.24, c 2+239 SB famati 10man -32 -4.15 -4.25 -22.00, c 2+1.42 - nHg famati famati famati 22.00, c 2+1.42 -	AP = 25 (P = 0.5 P benerve 10 20 4.5 15 15 15 15 15 15 15 15 15 15 15 15 15	60 1044 13 52 457 62, 41* 0 P re ution Total	1 -4.5 -4.79 2.9 + 2 cduc Events	100 10 21 22 13 17.25 100 100 100 100 100 100 100 10	104ad 54 51 171 296 7 = 80 11	Weight 359% 259% 325% 100.0%	Fam Mean Difference N, Kandons, 195-0, 050 (1-40, -0-52) -0.00 (-47, -1.30) -0.00 (-47, -1.30) -0.00 (-47, -1.30) -0.00 (-47, -1.30) -0.00 (-4, -0.00) -0.00 (-5, -0.00) -0.00	Head Difference N. Ranal Dimension Favors Control Mean Difference N. Random, 99%-CI -100 - 60 - 50 - 11 -100 - 50 - 50 - 50 - 50 - 50 - 50 - 50
Ender or subgroup Subg	10.24, c 2 × 239 8 SB Renat -42 -4.1 -4.1 -4.1 -4.25 22.00, c 2 × 1.02 nHg Renat Even	AP = 25 (P = 0.5 P benerve 50 27 4.5 15.11 MP = 22 P = 0.5 SB Demerve at 4 5 5 5 5 5 5 5 5 5 5 5 5 5	57, 47- 0 10 13 13 13 15 15 15 15 15 15 15	1 46 -3 -429 2/9 +2 cduo Exent	21 22 13 17,25 100011,1 etio	Total 14 54 51 171 290 P= 80 Th 10 11	0.5% 0.5% 25.3% 22.5% 100.0% %	Fact Mode Uthermore N. Bandows, BPK-CI -13361 44 66, 46 78, 20 -0351 44 78, 46 78, 20 -0351 44 78, 47 73 -0301 44 78, 47 73 -0301 44 78, 47 73 -0301 44 78, 47 73 -0301 58 800 -0301 58 800 -0.48 (0.58, 278) -0.48 (0.58, 278)	180 - 48 8 69 100 R Ranal Demonstran Favors Control Misan Difference Misan Differ
Staty or Salapove Salay or Salapove Prosobate 2012 Roma 2012 Roma 2012 Brendistry 2 Brendistry 2 Brendistry 2 Brendistry 2 Brendistry 2 Total (BO-C) Holdmain 2015 Protochairo 2012 Brendistry 2 Salapove Brendistry 2 Brendistry 2	10.24, c 2 × 239 SB Remail main -32 -4.1 -4.1 -4.15 21.00, C Z × 1.82 Name Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail Remail	27 9 = 0.5 9 = 0.5 10 15 15 15 15 15 15 15 15 15 15	57, 47- 6 10 13 53 55 55 55 55 65 7 rc 13 55 55 55 55 55 55 55 55 55 5	1 -46 -3 -479 2/P +3 cduc Con Events	17 21 21 22 19 17 25 10 17 25 10 17 10 17 10 10 10 10 10 10 10 10 10 10 10 10 10 1	Todal 14 51 171 290 P= 80 P= 8	0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Face Mean Difference N. Random, 1915-CI 0.591-10, 2021 0.591-10, 2021 -1.291-1483, 1071 -1.291-1483, 1071 -1.291-1483, 1071 -1.291-1483, 1071 -0.048, 8440 M.R. Random, 1915-CI 0.34.0.36, 22382 0014-34, 322, 2282 0121-44, 42, 22382 0121-44, 42, 42, 22382 0121-44, 42, 42, 22382 0121-44, 42, 42, 22382 0121-44, 42, 42, 42, 42, 42, 42, 44, 44, 44,	100 - 40 8 60 100 R Renal Elemenation Favors Control Mean Difference Meanine, 99%-CI - 400 - 50 50 10 - 400 - 50 50 - 50 - 50 - 50 - 50 - 50 -
Comparing Safe Comparin	10.24, c 2 × 2.20 SB Samat Manan -32 -4.1 -4.75 -22.00, C 2 × 1.82 -4.1 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 -4.75 	AP = 25 (P = 0.5 P benerve 50 20 4.5 15 15 15 15 15 15 15 15 15 1	57, 87- 0 10 10 13 52 85 253 467 62, 87+ 0 P rc 10 10 13 52 85 253 467 10 13 52 85 253 467 10 10 10 10 10 10 10 10 10 10	2/P + 2 -4.5 -4.79 2/P + 2 -4.79 2/P + 2 -4.79 2/P + 2 -4.79 2/P + 2 -4.79 2/P + 2 -4.79 2/P + 2 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.	atbol 50 21 52 52 18 57 25 21 800rg 10 50 50 50 50 50 50 50 50 50 5	Todal 14 54 171 290 P= 80 P= 90 P= 90 P P= 90 P P= 90 P P= 90 P P= 90 P P= 90 P P= 90 P P P= 90 P P P P= 90 P P P P P P P P P P P P P P P P P P P	976-976 35.76 35.75 32.576 32.576 32.576 32.576 376,776 276,776	Fact Mode Unformation 10.001 (44.06, 46.07, 201 0.401 (44.06, 46.07, 201 0.401 (44.07, 47.130) -1.001 (44.07, 47.130) -1.001 (44.07, 47.130) -0.221 (46.04, 64.01) Ten Odds Ratio 0.44 (0.06, 2.24) 0.44 (0.26, 2.24) 7.402 (0.67, 2.24) 7.402 (0.7, 2.24)	160 - da 8 60 100 Is Ranal Exerustion Faxors Control Misao Difference Misao Diffe
Comparing Safe Comparin	10.24, c 2 × 2.20 SB Renat 32 -4.1 -4.1 -4.1 -4.25 22.00, C 2 × 1.82 nHg Renat	AP = 25 (P = 0.3 Demention 10 20 4.5 15 15 15 15 15 15 15 15 15 15 15 15 15	57, 8°- 0 fion 13 52 63 253 467 C0, 457 C0, 457 P rcc 13 63 13 63 254	1 -46 -3 -479 2/P +3 cduc Con Events	atbol 50 21 52 52 13 57 25 21 10 17 15 10 17 15 17 17 17 17 17 17 17 17 17 17	Total 14 54 51 171 296 P=80 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	976-986 353% 3233% 325% 1960% 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Face Mean Difference N. Renders, 1915-CI 0.591-162, 2019 0.591-162, 2019 -1.291-1428, 1057 -1.291-1428, 1057 -1.291-1428, 1057 -1.291-1428, 1057 -1.291-1428, 1057 -0.041.048, 2.2019 0.041.048, 2.2019 7.401.042, 2.213 -1.401, 2.2, 2.131 -1.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.401, 2.	Head Differentiation Favors Control Head Difference Wead Difference Differe
Comparing Safe Comparin	18.24, c 2+2.28 SB 8mai -32 -4.1 -4.15 22.89, C 2+1.82 nHg 8mai 8mai	Ar* = 35 P benerva 50 27 4.5 15 15 15 15 15 15 15 15 15 1	57, 8°- 0 10 13 52 487 52 487 52 487 50 P rc 13 13 15 15 15 15 15 15 15 15 15 15	Content of the second s	1000011 21 22 13 13 13 13 10 10 10 10 10 10 10 10 10 10	Total 14 54 51 171 296 P=00 T 1 296 1 296 1 1 296 1 1 296 1 1 1 1 1 1 1 1 1 1 1 1 1	Weight 85% 25.3% 32.5% 186.0% %	Fact Mass Differences N, Randow, US-CI (23)89 (44.66, 45.20) (48)(41.76, 13.80) (48)(41.76, 13.80) (48)(41.76, 13.80) (48)(41.76, 13.80) Colds Ratio Did (48.46, 42.90) (14.47, 42.9	180 - 48 8 69 100 R Renal Demension Favors Control Mean Difference Mean
The second	18.24; c 2 × 2 28 SB Renal 1888 - 42 - 42 - 41 - 42 - 42 - 42 - 42 - 42 - 42 - 42 - 42	AP = 35 P P beserve 10 27 45 15 15 11 11 11 11 15 11 15 11 15 11 15 11 15 11 15 11 15 15	57, 8°- 0 files 13 3544 13 52 85 355 467 5 Prc titles 1 354 425	Con Events 1 -4.5 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -4.5 -5 -5 -5 -5 -5 -5 -5 -5 -5 -	settori 50 21 32 18 57.25 500011 19 500011 1048 50 51 51 51 51 51 50 50 50 50 50 50 50 50 50 50	Total 14 54 51 171 290 P= B0 P= B0 P= B0 0 24 5 10 14 54 51 171 14 54 51 171 14 54 51 171 14 54 51 171 14 54 51 171 14 54 51 171 190 19 19 19 19 19 19 19 19 19 19	Vinegati 85% 25.2% 12.5% 180.0%	Face Mean Difference 7, Random, 1915-C 0.51 (+12, 24) -0.51 (+12, 24) -1.51 (+12, 14) -1.51 (+12, 14)	Head Difference N Renal Deservation Favors Control Head Difference N Renalms, 95% CI
Teacher owner failer Teacher owner differ	19.25, c 2×2.200 5 SB fonati 1000 -32 -41 -4.75 22.00, c 2×1.62 fonati 1000 for for for for for for for for for for	Ar* = 35 P P beserve 10 20 448 15 15 11 15 11 15 11 15 11 15 11 15 11 15 11 15 11 15 11 15 11 15 11 15 15	57, 8°- 0 10 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 13 52 52 52 52 52 52 52 52 52 52	Com 1 466 -3 -4.79 209-43 Com Com Com 1 1 1 209-43 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.65 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -4.79 -	100001 100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 1100001 11000000 11000000 11000000 110000000 1100000000	Total 14 54 51 171 2980 P= 80 P= 80	Weight 353% 353% 353% 325% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 5005% 500	Fact Mass Difference N, Bandow, 1915. Cl (32)80144.05, (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (43), (4	160 - 48 6 50 100 In Renal Determation Favors Control Misan Difference Misan Diff

CONCLUSIONS Resistant hypertension treated with catheter-based RDN respond well to blood pressure reduction and with sustained control. It is yet to be determined if some RDN catheters are capable to provide more concise results and therefore lead to better procedural outcomes. Therefore more randomized clinical data are warranted.

CATEGORIES ENDOVASCULAR: Hypertension Therapies and Renal Denervation

KEYWORDS Renal denervation, Resistant hypertension

TCT-771

Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study

Melvin Lobo,¹ Joseph Montarello,² Manish Saxena,³ Ajay Jain,⁴ Darren Walters,⁵ Matthew W. Pincus,⁶ Stephen G. Worthley⁷ ¹William Harvey Research Institute, London, United Kingdom; ²Royal Adelaide Hospital, Adelaide, Australia; ³BartsHealth NHS Trust, London, UK; ⁴Barts Health NHS Trust, London, United Kingdom; ⁵Prince Charles Hospital, Brisbane, Brisbane, Qld; ⁶The Prince Charles Hospital, Chermside, Queensland; ⁷The University of Adelaide, Adelaide, Australia

BACKGROUND Percutaneous sympathetic renal artery denervation is available for the treatment of patients with resistant hypertension and preserved renal function. We investigated the safety and efficacy of a